Jun 22, 2011 · One frequently reads that an adverse effect may occur if a certain drug is given to someone who is already taking cyp3a inhibitors or inducers. Answer this question The information on this page reflects personal experiences shared by our community members.

Avoid using this medicine with strong or moderate CYP3A inducers. CYP3A substrates: If Journavx is used together with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, then you should refer to the Prescribing Information for the CYP3A substrates for dosing instructions.

Feb 26, 2025 · CYP3A Substrates. The plasma levels of simvastatin, a CYP3A substrate, and its active metabolite are increased by 100% in healthy volunteers receiving 80 mg once daily and RANEXA 1000 mg twice daily [see Drug Interactions (7.2)]. Mean exposure to atorvastatin (80 mg daily) is increased by 40% following co-administration with RANEXA (1000 mg ...

Mar 12, 2024 · Use of CERDELGA is contraindicated, to be avoided, or requires dosage adjustment in patients taking CYP2D6 or CYP3A inhibitors, depending on CYP2D6 metabolizer status, type of inhibitor, or degree of hepatic impairment [see Dosage and Administration (2.3), Contraindications (4), Drug Interactions (7.1)].

Adverse Reactions with Concomitant Use with CYP3A Inhibitors: Concomitant use with strong or moderate CYP3A inhibitors increased vanzacaftor, tezacaftor, and deutivacaftor exposure, which may increase the risk of ALYFTREK associated adverse reactions. Reduce the ALYFTREK dosage with concomitant use.

PAXLOVID which includes nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro: also referred to as 3CL pro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression …

Feb 10, 2025 · Concomitant use of potent CYP3A inducers that can significantly reduce nirmatrelvir or ritonavir plasma concentrations and result in potential loss of virologic response and possible resistance; these drugs include, but are not limited to, apalutamide, carbamazepine, phenobarbital, primidone, phenytoin, lumacaftor/ivacaftor, rifampin ...

Mar 10, 2025 · Cautions for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Contraindications. Concomitant use with drugs highly dependent on CYP3A for metabolism and for which elevated plasma concentrations are associated with serious and/or life-threatening events (e.g., alfuzosin, ergot alkaloids, lovastatin, lurasidone, oral midazolam, pimozide, …

Nov 10, 2024 · Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling. P-glycoprotein (P-gp) Substrates. Clinical Impact

Nov 25, 2024 · While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers. Sensitive Cytochrome P450 2C9 (CYP2C9) substrates Attruby inhibits CYP2C9 and may result in an increase in CYP2C9 substrate concentrations when these drugs are both ...